Radiopharm Theranostics Limited American Depositary Shares Cash Flow-to-Debt Ratio
Radiopharm Theranostics Limited American Depositary Shares cash flow-to-debt ratio. Radiopharm Theranostics Limited American Depositary Shares (RADX) has a Cash Flow-to-Debt Ratio of -0.85x as of June 2026, meaning its operating cash flow of $-32.08 Million could theoretically repay -1% of its total liabilities ($37.81 Million) in one year. See RADX financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Radiopharm Theranostics Limited American Depositary Shares (2022–2026)
Cash flow-to-debt ratio of Radiopharm Theranostics Limited American Depositary Shares from 2022 to 2026. Historical debt coverage capacity for Radiopharm Theranostics Limited American Depositary Shares across 5 annual periods. Also explore Radiopharm Theranostics Limited American (RADX) equity growth momentum to track the company's year-over-year net asset growth rate.
Radiopharm Theranostics Limited American Depositary Shares Cash Flow-to-Debt Ratio by Year (2022–2026)
Radiopharm Theranostics Limited American Depositary Shares cash flow-to-debt ratio by year from 2022 to 2026. Year-by-year debt coverage analysis for Radiopharm Theranostics Limited American Depositary Shares. For the full cash flow conversion analysis, see Radiopharm Theranostics Limited American (RADX) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2026 | -1.37x | $-51.63 Million | $37.81 Million | ▼ -62.5% |
| 2025 | -0.84x | $-36.65 Million | $43.61 Million | ▼ -63.4% |
| 2024 | -0.51x | $-22.98 Million | $44.68 Million | ▲ +34.9% |
| 2023 | -0.79x | $-23.20 Million | $29.37 Million | ▼ -62.7% |
| 2022 | -0.49x | $-9.92 Million | $20.42 Million | — |